Table 1.
Tested carbapenem | Number of isolates tested (% of all isolates) | Isolates tested “susceptible” (% with 95% CI)a | Isolates tested “intermediate” (% with 95% CI)a | Isolates tested “resistant” (% with 95% CI)a | Isolates tested “non-susceptible” (% with 95% CI)a |
---|---|---|---|---|---|
Meropenem | 150,746 (97.4%) | 99.58% (99.49, 99.65%) | 0.09% (0.07, 0.12%) | 0.33% (0.27, 0.40%) | 0.42% (0.35, 0.51%) |
Imipenem | 150,114 (97.0%) | 99.62% (99.54, 99.69%) | 0.11% (0.09, 0.14%) | 0.27% (0.22, 0.34%) | 0.38% (0.31, 0.46%) |
Ertapenem | 56,560 (36.6%) | 98.95% (98.68, 99.16%) | 0.11% (0.08, 0.16%) | 0.94% (0.74, 1.2%) | 1.05% (0.84, 1.32%) |
At least one carbapenemb | 154,524 (99.9%) | 99.37% (99.24, 99.49%) | 0.11% (0.08, 0.13%) | 0.52% (0.42, 0.64%) | 0.63% (0.51, 0.76%) |
a 95% CI calculated accounting for clustering on hospital level
bMeropenem, imipenem or ertapenem